The Premium On CVS Stock Vs What Its Peers Deliver

The health care giant commands a premium price over its rivals, but its core numbers tell a different story. Is the market seeing a future that isn’t in the results yet?

CVS Health (CVS) is far more than the corner drugstore. It’s a sprawling health services company, combining a large insurance arm in Aetna, a powerful pharmacy benefit manager in Caremark, and thousands of retail locations. After a twelve-month run that saw its stock return +62%, shares now trade around $104.15. That performance, however, has created a stark contradiction. Within its competitive group, why does CVS Health carry one of the richest valuations while ranking lower on growth and margins?

How can the priciest stock have the weakest margins?

The numbers create a clear mismatch. CVS trades at 45.2 times its trailing earnings, a significant premium to its direct competitor, UnitedHealth Group (UNH), which trades at 32.0 times earnings. Yet on the metrics that typically justify such a price, CVS lags. UnitedHealth delivered higher revenue growth over the last twelve months, at 9.7% versus 7.6% for CVS.

The gap is even wider on profitability. UnitedHealth’s operating margin stands at 4.2%, while CVS manages just 2.9%. The market is paying a top-tier price for a business that, by these core measures, is not the top-tier operator in its group. This isn’t a subtle difference; it’s a direct challenge to the ranking.

Is the market betting on a health care ecosystem no one else can build?

The premium valuation isn’t random; it’s a bet on the company’s unique, vertically integrated strategy. The strongest argument for the market’s pricing is the turnaround taking shape in the company’s Health Care Benefits segment. Management recently highlighted that they “drove over $1 billion of year-over-year AOI improvement at Aetna,” a sign that its efforts to restore profitability are gaining traction. A recent analysis of peer UnitedHealth suggests its own stock price may not fully reflect its business reality.

CVS is also investing heavily in technology to tie its disparate parts together. It plans to launch Health100, an “AI native, state-of-the-art technology and service platform” intended to create a seamless experience for consumers. The market is pricing in the potential for this integrated model to deliver more predictable, defensible earnings down the road. For investors who prefer the broader theme of health care services over a single company’s execution risk, an ETF like IHF offers exposure to the entire sector.

But this forward-looking story comes with a significant catch. Management has openly stated that the latest government reimbursement rates for its Medicare Advantage business are “insufficient to offset underlying medical cost trends.” This pressure from Washington directly threatens the Aetna margin recovery that bulls are counting on, making the company’s high valuation seem premature.

Can Aetna’s margins justify the premium?

Ultimately, the debate over CVS’s valuation comes down to whether its execution can overcome the external pressures on its insurance business. The company’s recent performance gave it the confidence to increase its full-year 2026 adjusted EPS guidance to a range of “$7.30 to $7.50,” signaling management believes it can navigate the challenges.

The one number that will settle the argument is the medical benefit ratio (MBR) for the Health Care Benefits segment. Despite a strong first quarter, management is holding its full-year MBR guidance within a range of “90.5%, plus or minus 50 basis points.” If CVS can hold or beat that line while Medicare rates remain tight, it will prove its cost controls are working, and the integrated model is delivering. If the MBR deteriorates, the stock’s premium price will be much harder to defend.

This piece pulled one thread; our full peer-by-peer dashboards for CVS lay every metric side by side, updated daily.

Even The Best Of The Group Is Still One Stock

Whichever name wins a peer comparison, buying it concentrates you in one company and one industry, and industries move together: when the group catches a cold, the best house on the block still sneezes.

The Trefis High Quality (HQ) Portfolio diversifies across roughly 30 quality names in different industries, selected on fundamentals and re-balanced with discipline, so no single group’s weather decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Use the comparison to understand the stock; use the portfolio to own the market’s best.